問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
張建仁
下載
2025-11-01 - 2030-12-31
Condition/Disease
The efficacy of lunsekimig was assessed by measuring the annualized incidence of moderate to severe COPD exacerbations.
Test Drug
Lunsekimig/ SAR443765
Participate Sites8Sites
Not yet recruiting1Sites
Recruiting7Sites
2023-12-01 - 2027-12-31
Participate Sites6Sites
Recruiting6Sites
2024-01-01 - 2032-12-31
Participate Sites5Sites
Not yet recruiting3Sites
Recruiting1Sites
2022-01-01 - 2031-02-27
Recruiting8Sites
2022-02-01 - 2029-12-31
Participate Sites9Sites
Recruiting9Sites
2018-10-01 - 2026-12-31
Participate Sites12Sites
Recruiting12Sites
Division of Thoracic Medicine
2023-09-01 - 2029-12-31
Participate Sites13Sites
Recruiting13Sites
2022-01-01 - 2026-12-31
Participate Sites10Sites
Recruiting10Sites
2023-02-01 - 2026-12-31
2021-02-06 - 2026-12-31
Participate Sites4Sites
Recruiting4Sites
全部
